Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Molecular and Cellular Pathobiology

Basal but not Luminal Mammary Epithelial Cells Require PI3K/mTOR Signaling for Ras-Driven Overgrowth

Kristin A. Plichta, Jessica L. Mathers, Shelley A. Gestl, Adam B. Glick and Edward J. Gunther
Kristin A. Plichta
1Jake Gittlen Cancer Research Foundation, 2Penn State Hershey Cancer Institute, and 3Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania; and 4The Center for Molecular Toxicology and Carcinogenesis, Pennsylvania State University, University Park, Pennsylvania
1Jake Gittlen Cancer Research Foundation, 2Penn State Hershey Cancer Institute, and 3Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania; and 4The Center for Molecular Toxicology and Carcinogenesis, Pennsylvania State University, University Park, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica L. Mathers
1Jake Gittlen Cancer Research Foundation, 2Penn State Hershey Cancer Institute, and 3Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania; and 4The Center for Molecular Toxicology and Carcinogenesis, Pennsylvania State University, University Park, Pennsylvania
1Jake Gittlen Cancer Research Foundation, 2Penn State Hershey Cancer Institute, and 3Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania; and 4The Center for Molecular Toxicology and Carcinogenesis, Pennsylvania State University, University Park, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shelley A. Gestl
1Jake Gittlen Cancer Research Foundation, 2Penn State Hershey Cancer Institute, and 3Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania; and 4The Center for Molecular Toxicology and Carcinogenesis, Pennsylvania State University, University Park, Pennsylvania
1Jake Gittlen Cancer Research Foundation, 2Penn State Hershey Cancer Institute, and 3Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania; and 4The Center for Molecular Toxicology and Carcinogenesis, Pennsylvania State University, University Park, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam B. Glick
1Jake Gittlen Cancer Research Foundation, 2Penn State Hershey Cancer Institute, and 3Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania; and 4The Center for Molecular Toxicology and Carcinogenesis, Pennsylvania State University, University Park, Pennsylvania
1Jake Gittlen Cancer Research Foundation, 2Penn State Hershey Cancer Institute, and 3Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania; and 4The Center for Molecular Toxicology and Carcinogenesis, Pennsylvania State University, University Park, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward J. Gunther
1Jake Gittlen Cancer Research Foundation, 2Penn State Hershey Cancer Institute, and 3Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania; and 4The Center for Molecular Toxicology and Carcinogenesis, Pennsylvania State University, University Park, Pennsylvania
1Jake Gittlen Cancer Research Foundation, 2Penn State Hershey Cancer Institute, and 3Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania; and 4The Center for Molecular Toxicology and Carcinogenesis, Pennsylvania State University, University Park, Pennsylvania
1Jake Gittlen Cancer Research Foundation, 2Penn State Hershey Cancer Institute, and 3Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania; and 4The Center for Molecular Toxicology and Carcinogenesis, Pennsylvania State University, University Park, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/0008-5472.CAN-12-1635 Published November 2012
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    MMTV-rtTA and K5-rtTA restrict transgene expression to opposing MEC compartments. Organoids prepared from Dox-naïve bitransgenic mice engineered for basal MEC-restricted labeling (K5-rtTA/TGFP; BasalGFP) or luminal MEC-restricted labeling (MMTV-rtTA/TGFP; LuminalGFP) were cultured in 3D. A, compartment-restricted MEC labeling. Live cell images (×20) of representative organoids captured before and after Dox-induced reporter gene expression are shown. Bar, 100 μm. B, confirmation of compartment-restricted labeling by confocal microscopy. Organoids were recovered after 7 days of Dox treatment in 3D culture. Equatorial confocal images (×63) of representative BasalGFP and LuminalGFP organoids are shown. Bar, 20 μm. C, live cell imaging of MEC proliferation and death. Time-lapse images (×20) depict typical MEC mitosis and cell death events captured during extended imaging of a Dox-treated BasalGFP organoid. Bar, 20 μm.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    H-RASG12V expressed in either MEC compartment drives organoid overgrowth. A, normal histomorphology of Dox-naïve transgenic mammary glands. Representative images of camine-stained mammary gland whole mounts and immunohistochemically stained tissue sections are shown. White bar, 500 μm; black bar, 100 μm. B, time-lapse imaging of organoid overgrowth. Organoids prepared from Dox-naïve mice engineered for Ras pathway activation in either basal MECs (K5-rtTA/TGFP/TRAS; BasalRAS/GFP) or luminal MECs (MMTV-rtTA/TGFP/TRAS; LuminalRAS/GFP) were cultured concurrently in 3D along with genetic control organoids lacking the TRAS transgene (BasalGFP and LuminalGFP). Sequential images of representative organoids of each genotype captured during a 1 week live-cell imaging experiment are shown. Times denote hrs after Dox addition. Bar, 50 μm. C, Ras-mediated changes in organoid size and shape. 2D organoid images captured after 6 days of Dox treatment were subjected to morphometric analysis to determine mean organoid area (left) and circularity (right). Mean values reflect analysis of 23 to 111 organoids for each genotype and treatment condition. D, Ras-mediated increases in MEC proliferation and survival. Organoid videos were viewed frame-by-frame to score mitotic (left) and cell death (right) events occurring during the first 2 days of Dox treatment. Mean values reflect indices (events per organoid, normalized to a 24-hour acquisition period) derived from analyzing videos from 8 to 38 organoids of each genotype. *, P < 0.01; **, P < 0.05; Kruskal–Wallis analysis of variance, Tukey–Kramer method. All error bars indicate SEM.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    H-RASG12V, but not Fgf2, triggers focal invasion into Matrigel. A, Fgf2-induced multilayered epithelial elongation. Still image from a live cell imaging experiment depict a representative luminalGFP organoid 7 days after initiating Fgf2-induced branching morphogenesis. B, Ras-mediated focal invasion. Time-lapse images depict leader cells initiating invasion. Arrowheads mark protrusions emanating from leader cells indicated by white arrows. Red arrows indicate follower “stalk” cells. Bar, 25μm. C, quantification of Ras-mediated focal invasion. Organoids of the indicated genotypes were cultured in the presence and absence of Dox for 6 days, then scored for the presence of focal invasion as described in Materials and Methods. Mean values reflect analysis of 20 to 77 organoids for each genotype and treatment condition. D, contrasting modes of collective MEC invasion triggered by Fgf2 versus H-RASG12V. Organoids of the indicated genotypes underwent Fgf2-induced branching before Dox treatment. Panels depict morphology of a representative organoid before and after Dox-induced transgene expression.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    MEK inhibition partially blocks Ras phenotypes in both MEC compartments. BasalRAS/GFP and luminalRAS/GFP organoids were cultured under the indicated treatment conditions for 6 days. PD denotes MEK inhibitor PD0325901 at 100 nmol/L. Left panels depict day 6 images (×10) of representative organoids for each genotype and treatment condition (see also Videos 5 and 6). Morphometry of 2D images captured at days 0, 2, 4, and 6 were used to determine the prevalence of focal invasion as well as the mean organoid circularity and area at each time point. Each data point reflects the analysis of 37 to 55 organoids. Error bars denote SEM.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    PI3K/mTOR inhibition fully blocks Ras phenotypes in basal but not luminal MECs. BasalRAS/GFP and luminalRAS/GFP organoids were cultured under the indicated treatment conditions for 6 days. Left panels depict day 6 images (×10) of representative organoids for each genotype and treatment condition (see also Videos 7–10). Morphometry of 2D images captured at days 0, 2, 4, and 6 were used to determine the prevalence of focal invasion as well as the mean organoid circularity and area at each time point. A, PI3K pathway inhibition. LY denotes PI3K inhibitor LY294002 at 10 μmol/L. Each data point reflects the analysis of 24 to 47 organoids. B, mTOR pathway inhibition. Rap denotes Rap at 5 nmol/L. Each data point reflects the analysis of 18 to 114 organoids. Error bars denote SEM.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Suppressing Ras-driven phenotypes involves decreased proliferation and preservation of MEC compartments. BasalRAS/GFP and luminalRAS/GFP organoids were cultured under the indicated treatment conditions in 3D. Mitotic and cell death events were scored during the first 2 days of Dox treatment. A, MEK inhibitor effects on MEC proliferation and survival. PD denotes MEK inhibitor PD0325901 at 100 nmol/L. B, PI3K/mTOR inhibitor effects on MEC proliferation and survival. Mean values reflect indices (events per organoid, normalized to a 24-hour acquisition period) derived from analyzing videos from 11 to 34 organoids of each genotype. Error bars indicate SEM. C, PI3K/mTOR inhibitor effects on MEC compartmentalization. Organoids were recovered after 3D culture for 7 days, then fixed and stained with Hoechst and phalloidin. Panels depict equatorial confocal microscopy images (×63) of representative organoids of each indicated genotype and treatment condition. Bars, 50 μm. LY denotes PI3K inhibitor LY294002 at 10 μmol/L. Rap denotes Rap at 5 nmol/L.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    PI3k/mTOR blockade abrogates basal but not luminal MEC overgrowth across a range of Ras activation levels and inhibitor doses. BasalRAS/GFP and luminalRAS/GFP organoids were cultured under the indicated treatment conditions for 6 days. 2D image morphometry was used to determine mean organoid area. A, LY effects on organoid size across varied Dox doses. When administered, the LY dose was held constant at 10 μmol/L. B, Inhibitor effects on organoid size across varied drug doses. When administered, the Dox dose was held constant at 1,000 ng/mL. Mean values reflect analysis of 18 to 34 organoids for each genotype and treatment condition. Error bars denote SEM.

Additional Files

  • Figures
  • Supplementary Data

    Files in this Data Supplement:

    • Supplementary Video 1 - MOV file - 2MB, Live cell imaging of a K5-rtTA/TGFP organoid. Representative video depicting an organoid prepared from a Dox-na�ve basalGFP (K5-rtTA/TGFP) mouse cultured in 3D with Dox
    • Supplementary Video 2 - MOV file - 2.1MB, Live cell imaging of an MMTV-rtTA/TGFP organoids. Representative video depicting an organoid prepared from a Dox-naive luminalGFP (MMTV-rtTA/TGFP) mouse cultured in 3D with Dox
    • Supplementary Video 3 - MOV file - 2.1MB, ive cell imaging of H-RASG12V-driven basal MEC overgrowth. Representative video depicting an organoid prepared from a Dox-naive basalRas/GFP (K5-rtTA/TGFP/TRAS) mouse cultured in 3D with Dox
    • Supplementary Video 4 - MOV file - 1.7MB, Live cell imaging of H-RASG12V-driven luminal MEC overgrowth. Representative video depicting an organoid prepared from a Dox-naive luminalRas/GFP (MMTV-rtTA/TGFP/TRAS) mouse cultured in 3D with Dox
    • Supplementary Video 5 - MOV file - 2.1MB, Effects of MEK Inhibitor PD0325901 on Ras-driven basal MEC overgrowth. Representative video depicting an organoid prepared from a Dox-naive basalRas/GFP (K5-rtTA/TGFP/TRAS) mouse cultured in the presence of both Dox and PD0325901 in 3D
    • Supplementary Video 6 - MOV file - 2MB, Effects of MEK Inhibitor PD0325901 on Ras-driven luminal MEC overgrowth. Representative video depicting an organoid prepared from a Dox-naive luminalRas/GFP (MMTV-rtTA/TGFP/TRAS) mouse cultured in the presence of both Dox and PD0325901 in 3D
    • Supplementary Video 7 - MOV file - 1.7MB, Effects of Pi3k Inhibitor LY294002 on Ras-driven basal MEC overgrowth. Representative video depicting an organoid prepared from a Dox-naive basalRas/GFP (K5-rtTA/TGFP/TRAS) mouse cultured in the presence of both Dox and LY294002 in 3D
    • Supplementary Video 8 - MOV file - 1.6MB, Effects of Pi3k Inhibitor LY294002 on Ras-driven luminal MEC overgrowth. Representative video depicting an organoid prepared from a Dox-naive luminalRas/GFP (MMTV-rtTA/TGFP/TRAS) mouse cultured in the presence of both Dox and LY294002 in 3D
    • Supplementary Video 9 - MOV file - 2.3MB, Effects of mTor Inhibitor rapamycin on Ras-driven basal MEC overgrowth. Representative video depicting an organoid prepared from a Dox-naive basalRas/GFP (K5-rtTA/TGFP/TRAS) mouse cultured in the presence of both Dox and rapamycin in 3D
    • Supplementary Video 10 - MOV file - 2.4MB, Effects of mTor Inhibitor rapamycin on Ras-driven luminal MEC overgrowth. Representative video depicting an organoid prepared from a Dox-naive luminalRas/GFP (MMTV-rtTA/TGFP/TRAS) mouse cultured in the presence of both Dox and rapamycin in 3D
PreviousNext
Back to top
Cancer Research: 72 (22)
November 2012
Volume 72, Issue 22
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Basal but not Luminal Mammary Epithelial Cells Require PI3K/mTOR Signaling for Ras-Driven Overgrowth
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Basal but not Luminal Mammary Epithelial Cells Require PI3K/mTOR Signaling for Ras-Driven Overgrowth
Kristin A. Plichta, Jessica L. Mathers, Shelley A. Gestl, Adam B. Glick and Edward J. Gunther
Cancer Res November 15 2012 (72) (22) 5856-5866; DOI: 10.1158/0008-5472.CAN-12-1635

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Basal but not Luminal Mammary Epithelial Cells Require PI3K/mTOR Signaling for Ras-Driven Overgrowth
Kristin A. Plichta, Jessica L. Mathers, Shelley A. Gestl, Adam B. Glick and Edward J. Gunther
Cancer Res November 15 2012 (72) (22) 5856-5866; DOI: 10.1158/0008-5472.CAN-12-1635
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • miR-6883 Family Targets CDK4/6 to Suppress Cancer
  • Cancer-Associated Alterations in PPP2R4
  • PACE4 Splicing in Cancer
Show more Molecular and Cellular Pathobiology
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement